Osiris Therapeutics, Inc. Common Stock
OSIR
OSIR was delisted on the 16th of April, 2019.
64 hedge funds and large institutions have $117M invested in Osiris Therapeutics, Inc. Common Stock in 2013 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 24 increasing their positions, 17 reducing their positions, and 8 closing their positions.
147% more capital invested
Capital invested by funds: $47.4M → $117M (+$69.7M)
100% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 8
41% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 17
14% more funds holding
Funds holding: 56 → 64 (+8)
48% less call options, than puts
Call options by funds: $2.64M | Put options by funds: $5.03M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$19.5M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$5.55M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$4.78M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$3.12M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$2.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
-$2.54M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$349K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$269K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$266K |
| 5 |
Allianz Asset Management
Munich,
Germany
|
-$222K |
OSIR Hedge Fund Activity: Q3 2013 in Review
64 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Osiris Therapeutics, Inc. Common Stock (OSIR) for Q3 2013, worth a combined $117M — up 147% from $47.4M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new OSIR positions and 8 closed out — a net gain of 8 holders — while 24 added to existing stakes and 17 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $19.5M. The largest seller was Hood River Capital Management, exiting entirely with an estimated $2.54M sold.
- 64 institutional investors held Osiris Therapeutics, Inc. Common Stock (OSIR) as of Q3 2013, up from 56 in Q2 2013.
- Funds reported $117M of Osiris Therapeutics, Inc. Common Stock stock for Q3 2013, up 147% quarter-over-quarter.
- 16 funds opened new Osiris Therapeutics, Inc. Common Stock positions in Q3 2013 and 8 closed out, a net change of +8 holders.
- The largest Osiris Therapeutics, Inc. Common Stock buyer in Q3 2013 was Fidelity Investments, an estimated $19.5M added.
- The largest Osiris Therapeutics, Inc. Common Stock seller in Q3 2013 was Hood River Capital Management, an estimated $2.54M sold.
Based on aggregated 13F filings for Q3 2013.